CIK 0001341235 · Non-accelerated filer<br>Smaller reporting company
Aldeyra Therapeutics, Inc.
Sign in to watch- Ticker
- ALDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 781-761-4904
- Business address
- 23 BRADFORD STREET, SUITE 1, CONCORD, MA, 01742
- Former names
- Aldexa Therapeutics, Inc., Neuron Systems Inc
- 4 Open-market buy Director bought 20,000 shares at an average $5.89 ($117,805)
- 4 Open-market buy President and CEO bought 20,000 shares at an average $5.14 ($102,824)
- 4 Open-market buy Director bought 20,000 shares at an average $5.00 ($99,963)
- 4 Open-market buy Chief Medical Officer bought 5,000 shares at $5.06 ($25,311)
- 4 Open-market buy Chief Financial Officer bought 3,200 shares at $4.71 ($15,072)
- 4 Open-market buy Chief Commerical Officer bought 4,329 shares at $4.68 ($20,260)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Director sold 96,743 shares at $10.01 ($968,397)
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chief Financial Officer acquired 29,637 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 3,503 shares (grant or award)
- 4 Grant or award President and CEO acquired 250,000 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
Page 7 of 12 · 223 filings